A bedtime dose of ARB was better than a morning dose in improving baroreflex sensitivity and urinary albumin excretion - The J-TOP study

Kazuo Eguchi, Motohiro Shimizu, Satoshi Hoshide, Kazuyuki Shimada, Kazuomi Kario

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The hypothesis that the bedtime dosing of angiotensin receptor blocker (ARB) is superior to morning dose in improving baroreflex sensitivity (BRS) and urinary albumin/creatinine ratio (UACR) was tested in this study. Baroreflex sensitivity was measured at baseline and at 6th month (N = 109) and was found to increase in the bedtime-dose group (P = .004), but not in the morning-dose group. The correlations between the change in BRS and the change in UACR were insignificant in the morning-dose group (r = 0.17, P = .26), but were significant in the bedtime-dose group (r = -0.29, P = .04). In conclusion, the improvement of BRS could be one of the mechanisms by which bedtime dosing of ARB confers renal protection.

Original languageEnglish
Pages (from-to)488-492
Number of pages5
JournalClinical and Experimental Hypertension
Volume34
Issue number7
DOIs
Publication statusPublished - Dec 7 2012

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology

Cite this